Boehringer Acquires Rights to Potential CF Inhalation Gene Therapy

Boehringer Ingelheim has taken legal steps giving it the lead role in further development of a long-lasting, inhalation gene therapy for cystic fibrosis (CF), called BI 3720931, that stems from a public-private research effort begun in 2018. The 2018 agreement brought together Boehringer, the U.K. Cystic Fibrosis…

CF Trust, CF Foundation Launch Gene-editing Project

The U.K. Cystic Fibrosis Trust, in collaboration with the U.S. Cystic Fibrosis Foundation, is launching a new strategic research center (SRC) dedicated to studying gene editing as a potential treatment strategy for cystic fibrosis (CF). “Making gene editing a reality for people with CF will take the…

Liver Disease in CF Appears Linked to Problems in CFTR Protein

A unique interaction between CFTR — the protein defective in people with cystic fibrosis (CF) — and two pro-inflammatory proteins may explain why some CF patients develop liver disease, researchers reported. Their work suggests that the CFTR protein can act as an anchor, bringing certain proteins — including the pro-inflammatory…

Change in CF Treatment Patterns in UK Seen With Use of Kalydeco

Since the introduction of Kalydeco (ivacaftor) in the U.K., marked changes in treatment patterns for cystic fibrosis (CF) patients using the medication have become noticeable over time, a study reported. Specifically, people treated with Kalydeco were less likely to continue with other treatments, such as inhaled antibiotics or…

Featured Column

Don’t Overlook Emotional Wellness When Dealing With Chronic Illness

A banner for Lara's column, depicting a car on a road trip winding through a forest.
Living with a chronic illness can affect emotional wellness, writes columnist Lara Govendo, who offers up some ideas for managing both.

Read the Column

Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.